Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL - Test2 - elhamkhani - TriplyDB

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

http://www.wikidata.org/entity/Q56965918

about

The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Novel immunotherapies in lymphoid malignancies Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Immune Modulation in Hematologic Malignancies Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Primer on tumor immunology and cancer immunotherapy Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab Monoclonal antibodies in acute lymphoblastic leukemia Bispecific T-cell engagers for cancer immunotherapy.Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults Second-generation inhibitors of Bruton tyrosine kinase Recent advances and novel treatment paradigms in acute lymphocytic leukemia Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk Chimeric antigen receptor T cells for sustained remissions in leukemia Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.Recruiting cytotoxic T cells to folate-receptor-positive cancer cells.CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.Managing cytokine release syndrome associated with novel T cell-engaging therapies.A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell Toxicity management for patients receiving novel T-cell engaging therapies.Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.

P2860

Q26744280-5C89D453-7751-4D46-8627-0823B9651848 Q26764903-A8495077-EA6E-4B09-9C8D-2D44E8824454 Q26770391-5A2FB131-6FAF-47A0-BC2D-3FB71A0CE09B Q26775363-BD6A5914-2402-4677-8010-441801C6975F Q26775720-A508CE72-465B-422E-8459-BA6F879AAC33 Q26777394-B735A312-D07E-4606-9161-9B7205619095 Q26781328-0EB6916B-B5B2-4D2E-9297-E0100561E126 Q26785828-26641CD0-7707-4C2C-B25B-A342847C30E2 Q26795540-8C9228FA-AF26-43AE-8576-C196792D9FA0 Q26796307-ADDF7068-C710-4454-9F09-A45437FF07FB Q26828511-F0120BCC-9DED-4CD4-8A1D-6C492FFD91F1 Q26865838-9DED70A8-D886-4C70-89B5-71AAD0A41706 Q26993238-B8638186-7822-4AB2-9AB9-C31B82183736 Q27001126-03EE0E6A-5881-4C59-B95A-D8361847D984 Q27006773-9402DBD1-3C74-4E51-9ECF-46B289737C95 Q27013710-9C9C835A-8836-4E3C-B770-899A6846D7C5 Q27022540-DA804FBA-9592-454F-A858-BCE5ABAC7CB8 Q27693313-F30BF7AF-2C84-4EAE-AB1A-F530173626FB Q28072131-0D71C702-C7B7-4741-873D-6C54498E72A7 Q28075764-B0BA0416-CE7F-401A-9787-5683B174BCC8 Q28076118-697C15A4-3EEC-423A-A7CA-6FBF357899A0 Q28078076-4F2E2CF7-F9B4-47D1-BE49-E2AD1B949ABE Q28079934-53C4845A-45E3-48D3-BFEE-9FEA95289271 Q28547458-4CBBDF90-48B1-4169-8398-3D3764B2DBBC Q29617588-1146107C-3882-4E0E-ABA0-528AF0B3F9E0 Q30827633-26D691A7-62D6-4770-BAB9-1557266940BA Q31135534-A1CCA381-F6E6-4BBD-BC1D-4365353B0057 Q31143912-5586B4EA-144E-460D-8B55-9214290E696A Q33576953-555DE04D-F13D-4DC2-A68E-13F4A7677FC6 Q33585293-89C291D7-B722-4E68-AB89-889A52312173 Q33689478-933B8E0F-546B-402C-9056-906EBC10703C Q33828575-C0F5F53A-987C-485A-AA66-F72015BEEE3C Q33828594-ED2747EF-40A4-4F8D-A219-F6E7E1D24FCE Q33993517-D0669363-91F2-4527-A330-5D95CB769B64 Q34221898-A5D76415-24D8-4233-9D74-9530639BCE3A Q34227769-AEB60FA8-8915-43B3-BCA2-E86FC7511D55 Q34343346-47A9F03E-D408-4081-83A5-900826DC4BD0 Q34463419-7928AE8A-55E2-4349-B008-D987F823F394 Q34469099-4B4D653F-41DE-4225-9375-FA869FBBADF8 Q34532041-FA8082E2-A025-48D7-81C3-E3D222340E0F

P2860

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

http://www.wikidata.org/entity/Q56965918

description

im September 2012 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2012

@uk

name

Long-term follow-up of hematol ...... ents with MRD in B-lineage ALL

@en

Long-term follow-up of hematol ...... ents with MRD in B-lineage ALL

@nl

type

label

Long-term follow-up of hematol ...... ents with MRD in B-lineage ALL

@en

Long-term follow-up of hematol ...... ents with MRD in B-lineage ALL

@nl

prefLabel

Long-term follow-up of hematol ...... ents with MRD in B-lineage ALL

@en

Long-term follow-up of hematol ...... ents with MRD in B-lineage ALL

@nl

P1433

Q56965918-8B6C557F-A52A-4966-BD4B-8BE4F7043AAE

P1476

Q56965918-7B358EBF-DE00-4FC3-A7AE-387FB9F5513E

P2093

Q56965918-084DE689-8285-4704-8CF1-8D60D017CD5F

Q56965918-08F5D815-129D-4AE7-8A32-0F13E4933F0D

Q56965918-095970DA-C31F-452F-AA4D-8B405EBEF957

Q56965918-0B560D03-8DFA-4104-95A0-A8BEE7EE0144

Q56965918-0EAFC2CB-7802-4AD5-9CA2-AAF1B290E9B2

Q56965918-1286E818-D136-4E2C-BF78-2CA684DC347C

Q56965918-24316CD0-475E-4B66-BE59-012D60273FA0

Q56965918-6C536467-2D17-4E6D-9419-BEE9AB81E9DE

Q56965918-74BFED22-EBEA-430C-BFFA-B7F68D421680

Q56965918-7A334DA6-6ABD-4773-B174-4C82FCD0D432

P304

Q56965918-EEA88014-2ACE-4B75-A7F0-41D98FC7B700

P31

Q56965918-2A11EEE5-B84E-41F7-96B0-A194246BEF2F

P356

Q56965918-54F1692E-2CB3-44D6-92B4-9F1F46012A9D

P407

Q56965918-91F4C8BA-7D47-4228-9AC2-D4A6651A48FE

P433

Q56965918-1ADD3AE1-F827-4A1F-9C27-1FC5053FB1BD

P478

Q56965918-ADEF4670-63D7-4BE1-A26F-F857B99F82E8

P50

Q56965918-8C19742D-C338-47FB-9909-448AACE15B89

P577

Q56965918-B1091F5C-736D-46A7-B6E4-13633C4A3A58

P698

Q56965918-622931B7-9C31-49F2-BE27-3AD3F2129AD8

P356

BLOOD-2012-07-441030

P1433

P1476

Long-term follow-up of hematol ...... ents with MRD in B-lineage ALL

@en

P2093

A. Viardot

http://www.w3.org/2001/XMLSchema#string

D. Hoelzer

http://www.w3.org/2001/XMLSchema#string

D. Nagorsen

http://www.w3.org/2001/XMLSchema#string

E. Degenhard

http://www.w3.org/2001/XMLSchema#string

G. Riethmuller

http://www.w3.org/2001/XMLSchema#string

G. Zugmaier

http://www.w3.org/2001/XMLSchema#string

H. A. Horst

http://www.w3.org/2001/XMLSchema#string

H. Einsele

http://www.w3.org/2001/XMLSchema#string

M. Bruggemann

http://www.w3.org/2001/XMLSchema#string

M. Klinger

http://www.w3.org/2001/XMLSchema#string

P304

5185-5187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-07-441030

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Burmeister

P577

2012-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23024237

http://www.w3.org/2001/XMLSchema#string